

Alan S Gamis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7905443/publications.pdf>

Version: 2024-02-01

122
papers

3,545
citations

201385

27
h-index

149479

56
g-index

125
all docs

125
docs citations

125
times ranked

4158
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia. <i>JAMA Oncology</i> , 2022, 8, 79.	3.4	36
2	Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation. <i>Journal of Clinical Oncology</i> , 2022, 40, 772-783.	0.8	7
3	Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children's Oncology Group study. <i>Haematologica</i> , 2022, , .	1.7	7
4	Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children's Oncology Group experience. <i>Bone Marrow Transplantation</i> , 2022, 57, 445-452.	1.3	3
5	Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3-ITD+</i> Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. <i>Journal of Clinical Oncology</i> , 2022, 40, 2023-2035.	0.8	36
6	Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report. <i>Blood</i> , 2021, 137, 1050-1060.	0.6	10
7	MYOD1 as a prognostic indicator in rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29085.	0.8	5
8	Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. <i>Cancers</i> , 2021, 13, 2336.	1.7	30
9	<i>CEBPA</i> -bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group. <i>Blood</i> , 2021, 138, 1137-1147.	0.6	55
10	High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. <i>Blood</i> , 2021, 138, 2337-2346.	0.6	16
11	CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes. <i>Blood Advances</i> , 2021, 5, 4963-4968.	2.5	4
12	Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric <i>KMT2A</i> -Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531. <i>Journal of Clinical Oncology</i> , 2021, 39, 3149-3160.	0.8	40
13	Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29281.	0.8	6
14	Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF- κ B subunit RelA. <i>Proteomics - Clinical Applications</i> , 2021, , 2100072.	0.8	4
15	ETS Family Transcription Factor Fusions in Childhood AML: Distinct Expression Networks and Clinical Implications. <i>Blood</i> , 2021, 138, 2356-2356.	0.6	4
16	Significant Improvements in Survival for Patients with <i>t(6;9)(p23;q34)/DEK-NUP214</i> in Contemporary Trials with Intensification of Therapy: A Report from the Children's Oncology Group. <i>Blood</i> , 2021, 138, 519-519.	0.6	3
17	Epigenetic Silencing of CD34 in AML and Association with Outcome in <i>KMT2A</i> Fusions. <i>Blood</i> , 2021, 138, 802-802.	0.6	0
18	A Polygenic DNA Damage Repair Pharmacogenomics (DDR_PGx8) Score Predicts GO Response in AML. <i>Blood</i> , 2021, 138, 3456-3456.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431. Archives of Pathology and Laboratory Medicine, 2020, 144, 466-472.	1.2	9
20	Morphologic remission status is limited compared to \hat{I}^N flow cytometry: a Children's Oncology Group AAML0531 report. Blood Advances, 2020, 4, 5050-5061.	2.5	21
21	Acute erythroid leukemia is enriched in <i>NUP98</i> fusions: a report from the Children's Oncology Group. Blood Advances, 2020, 4, 6000-6008.	2.5	11
22	Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2020, 38, 2398-2406.	0.8	40
23	Comprehensive Transcriptome Profiling of Cryptic <i>CBFA2T3</i> - <i>GLIS2</i> Fusion Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study. Clinical Cancer Research, 2020, 26, 726-737.	3.2	42
24	Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG. Blood, 2020, 136, 31-32.	0.6	5
25	Failures and Successes in Pediatric Patients with Acute Myeloid Leukemia with First Relapse: A Large International Report on Current Treatment Strategies and Outcome. Blood, 2020, 136, 6-7.	0.6	1
26	Genome and Transcriptome Profiling of Monosomy 7 AML Defines Novel Risk and Therapeutic Cohorts. Blood, 2020, 136, 20-21.	0.6	1
27	ABC11 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial. Blood Cancer Journal, 2019, 9, 51.	2.8	26
28	Risk Markers for Significant Bleeding and Thrombosis in Pediatric Acute Promyelocytic Leukemia; Report From the Children's Oncology Group Study AAML0631. Journal of Pediatric Hematology/Oncology, 2019, 41, 51-55.	0.3	20
29	Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene - a COG/Tpaml Study. Blood, 2019, 134, 461-461.	0.6	12
30	Response to Sorafenib in FLT3/ITD AML Is Dependent on Co-Occurring Mutational Profile. Blood, 2019, 134, 119-119.	0.6	6
31	Area-Based Socioeconomic Disparities in Survival of Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Blood, 2019, 134, 703-703.	0.6	1
32	Effect of intensification of induction II chemotherapy and liberalization of stem cell donor source on outcome for children with high risk acute myeloid leukemia: A report from the Children's Oncology Group. Journal of Clinical Oncology, 2019, 37, 10002-10002.	0.8	2
33	Occurrence and Resolution of Anthracycline Cardiotoxicity and Impact on Treatment Outcomes Among Children Treated on the AAML1031 Clinical Trial: A Report from the Children's Oncology Group. Blood, 2019, 134, 331-331.	0.6	2
34	The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nature Medicine, 2018, 24, 103-112.	15.2	525
35	Effect of dexrazoxane on left ventricular function and treatment outcomes in patients with acute myeloid leukemia: A Children's Oncology Group report. Journal of Clinical Oncology, 2018, 36, 10501-10501.	0.8	3
36	Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report. Blood, 2017, 129, 3051-3058.	0.6	19

#	ARTICLE	IF	CITATIONS
37	Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26612.	0.8	33
38	Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. <i>Blood</i> , 2017, 129, 3304-3313.	0.6	71
39	Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531. <i>Haematologica</i> , 2017, 102, 2058-2068.	1.7	22
40	Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531. <i>Blood</i> , 2017, 130, 943-945.	0.6	16
41	Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. <i>Haematologica</i> , 2017, 102, e340-e343.	1.7	4
42	Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2017, 176, 86-91.	1.2	29
43	Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631. <i>Journal of Clinical Oncology</i> , 2017, 35, 3021-3029.	0.8	62
44	CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. <i>Journal of Clinical Oncology</i> , 2017, 35, 2674-2682.	0.8	120
45	Four versus five chemotherapy courses in patients with low risk acute myeloid leukemia: A Children's Oncology Group report.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10515-10515.	0.8	3
46	Comparing Analytic Methods for Longitudinal GWAS and a Case-Study Evaluating Chemotherapy Course Length in Pediatric AML. A Report from the Children's Oncology Group. <i>Frontiers in Genetics</i> , 2016, 7, 139.	1.1	2
47	Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group. <i>International Journal of Cancer</i> , 2016, 139, 1930-1935.	2.3	7
48	CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML. <i>Blood</i> , 2016, 127, 3094-3098.	0.6	49
49	miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2016, 63, 2096-2103.	0.8	21
50	Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2016, 34, 3766-3772.	0.8	17
51	CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. <i>Journal of Clinical Oncology</i> , 2016, 34, 747-755.	0.8	116
52	Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2016, 22, 1951-1957.	3.2	49
53	Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. <i>Cancer Research</i> , 2016, 76, 2197-2205.	0.4	133
54	A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. <i>Leukemia and Lymphoma</i> , 2016, 57, 1567-1574.	0.6	13

#	ARTICLE	IF	CITATIONS
55	Prognostic Significance of 11q23/MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML) - Results from the Children's Oncology Group (COG) Trial AAML0531. <i>Blood</i> , 2016, 128, 1211-1211.	0.6	14
56	Discovery and Validation of Cell-Surface Protein Mesothelin (MSLN) As a Novel Therapeutic Target in AML: Results from the COG/NCI Target AML Initiative. <i>Blood</i> , 2016, 128, 2873-2873.	0.6	5
57	The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group. <i>Blood</i> , 2016, 128, 899-899.	0.6	10
58	Relapse Following Initial Remission and Subsequent Outcome for Children with Relapsed Acute Myeloid Leukemia on the AAML0531 Phase III Study of Gemtuzumab Ozogamicin: A Report from the Children's Oncology Group. <i>Blood</i> , 2016, 128, 2794-2794.	0.6	0
59	A microRNA Expression-Based Model Predicts Event Free Survival in Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1210-1210.	0.6	0
60	High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. <i>Journal of Hematology and Oncology</i> , 2015, 8, 115.	6.9	46
61	Earlier initiation of antibiotic therapy: Does prophylaxis offer greater benefit in AML?. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1121-1122.	0.8	2
62	Immune-Related Conditions and Acute Leukemia in Children with Down Syndrome: A Children's Oncology Group Report. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 454-458.	1.1	5
63	Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group. <i>Cancer Genetics</i> , 2015, 208, 408-413.	0.2	3
64	Multimerin-1 (<i>MMRN1</i>) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2015, 21, 3187-3195.	3.2	18
65	Rearrangements in Nucleoporin Family of Genes in Childhood Acute Myeloid Leukemia: A Report from Children Oncology Group and NCI/COG Target AML Initiative. <i>Blood</i> , 2015, 126, 169-169.	0.6	2
66	Results of a Phase III Trial Including Arsenic Trioxide Consolidation for Pediatric Patients with Acute Promyelocytic Leukemia (APL): A Report from the Children's Oncology Group Study AAML0631. <i>Blood</i> , 2015, 126, 219-219.	0.6	3
67	ASXL1 and ASXL2 Mutations in Childhood AML Are Strongly Associated with t(8;21) but Do Not Independently Impact on Prognosis: A Report from the Children's Oncology Group and NCI/COG Target Initiative. <i>Blood</i> , 2015, 126, 2587-2587.	0.6	1
68	Hierarchical Clustering of Immunophenotypic Cell Surface Antigen Expression Identifies Clinically Meaningful Cohorts in Childhood AML: A Report from the Children's Oncology Group Protocol AAML0531. <i>Blood</i> , 2015, 126, 561-561.	0.6	3
69	Comprehensive Sequence Analysis of Relapse and Refractory Pediatric Acute Myeloid Leukemia Identifies miRNA and mRNA Transcripts Associated with Treatment Resistance - a Report from the COG/NCI-Target AML Initiative. <i>Blood</i> , 2015, 126, 687-687.	0.6	2
70	Discovery and Functional Validation of Novel Pediatric Specific FLT3 Activating Mutations in Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative. <i>Blood</i> , 2015, 126, 87-87.	0.6	19
71	Comparing the Utilization of Health Care Resources in Children with ALL and AML Based on Geographic Location: A Retrospective Analysis Utilizing the PHIS Database. <i>Blood</i> , 2015, 126, 3282-3282.	0.6	0
72	Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. <i>Journal of Clinical Oncology</i> , 2014, 32, 3021-3032.	0.8	360

#	ARTICLE	IF	CITATIONS
73	Acute myeloid leukaemia (<sc>AML</sc>) with t(6;9)(p23;q34) is associated with poor outcome in childhood <sc>AML</sc> regardless of <i>FLT3</i>â€¦TD status: a report from the Children's Oncology Group. British Journal of Haematology, 2014, 166, 254-259.	1.2	58
74	NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood, 2014, 124, 2400-2407.	0.6	99
75	CBFA2T3-GLIS2 Fusion Is Prevalent in Younger Patients with Acute Myeloid Leukemia and Associated with High-Risk of Relapse and Poor Outcome: A Childrenâ€™s Oncology Group Report. Blood, 2014, 124, 13-13.	0.6	19
76	An Analysis of CNS2 Patients with AML: Do They Require Additional Intrathecal Therapy? a Report from Childrenâ€™s Oncology Group Protocols AAML0531 and O3P1 and St Jude Childrenâ€™s Research Hospital Protocol AML02. Blood, 2014, 124, 277-277.	0.6	2
77	Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML) Have Increased Treatment-Related Mortality with Similar Outcomes – a Report from the Children's Oncology Group Trials AAML03P1 and AAML0531. Blood, 2014, 124, 3672-3672.	0.6	6
78	Influence of polymorphisms discovered in cell-based model of cytarabine sensitivity on outcome in pediatric AML: A Children's Oncology Group Study.. Journal of Clinical Oncology, 2014, 32, 10040-10040.	0.8	0
79	Standardized costs and outcome in children treated with gemtuzumab on the AAML0531 trial: A report from the Childrenâ€™s Oncology Group.. Journal of Clinical Oncology, 2014, 32, 7086-7086.	0.8	0
80	Correlation of Mir-155 Expression with Clinical Outcome in Childhood AML: A Report from Childrenâ€™s Oncology Group. Blood, 2014, 124, 3545-3545.	0.6	0
81	Gemtuzumab Ozogamicin (GO) in Infants with Acute Myeloid Leukemia (AML) â€“ Combined Results from the Childrenâ€™s Oncology Group (COG) Trials, AAML03P1 and AAML0531. Blood, 2014, 124, 377-377.	0.6	0
82	Pneumocystis Jirovecii Pneumonia (PCP) in Children with Cancer: A Retrospective Cohort Analysis from the Pediatric Health Information System (PHIS) Database, 2004-2009. Blood, 2014, 124, 4836-4836.	0.6	0
83	Patient Factors Associated with Enrollment on an Acute Myeloid Leukemia Phase III Clinical Trial: A Report from the Childrenâ€™s Oncology Group. Blood, 2014, 124, 2286-2286.	0.6	0
84	Accuracy Of Adverse Event Reporting Compared To Patient Chart Abstraction On a Phase III NCI-Funded Clinical Trial For Pediatric Acute Myeloid Leukemia: A Report From The Childrenâ€™s Oncology Group. Blood, 2013, 122, 931-931.	0.6	1
85	Genomic Architecture and Treatment Response In Pediatric Acute Myeloid Leukemia: A Report From The Childrenâ€™s Oncology Group. Blood, 2013, 122, 610-610.	0.6	0
86	Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood, 2012, 120, 1581-1588.	0.6	256
87	Transient myeloproliferative disorder in children with <sc>D</sc>own syndrome: clarity to this enigmatic disorder. British Journal of Haematology, 2012, 159, 277-287.	1.2	70
88	Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reducedâ€¦dose chemotherapy on Children's Oncology Group trial A2971. Cancer, 2012, 118, 4806-4814.	2.0	72
89	A Phase 2 Study of Bortezomib Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid Leukemia: A Children's Oncology Group (COG) Study. Blood, 2012, 120, 3580-3580.	0.6	4
90	Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood, 2011, 118, 6752-6759.	0.6	182

#	ARTICLE	IF	CITATIONS
91	Leukemic mutations in the methylation-associated genes <i>DNMT3A</i> and <i>IDH2</i> are rare events in pediatric AML: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2011, 57, 204-209.	0.8	109
92	Single Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Pediatric Patients with De Novo Acute Myeloid Leukemia (AML): Validation Study Results. <i>Blood</i> , 2011, 118, 3544-3544.	0.6	1
93	Presence of Residual Disease Detected by Multidimensional Flow Cytometry Identifies Patients with AML At High Risk of Relapse – a Report From the Children's Oncology Group. <i>Blood</i> , 2011, 118, 3545-3545.	0.6	1
94	Multidimensional Flow Cytometry Significantly Improves Upon the Morphologic Assessment of Post-Induction Marrow Remission Status – Comparison of Morphology and Multidimensional Flow Cytometry; A Report From the Children's Oncology Group AML Protocol AAML0531. <i>Blood</i> , 2011, 118, 939-939.	0.6	4
95	The Ratio of Alternate BIRC5 (Survivin) Splice Variants Correlates with Refractory Disease and Poor Outcome in Children with Acute Myeloid Leukemia: A Report From the Children's Oncology Group. <i>Blood</i> , 2011, 118, 3555-3555.	0.6	0
96	Merging of Children's Oncology Group and Pediatric Health Information Systems Data to Determine Resource Utilization and Treatment Costs on AAML0531: A Report From the Children's Oncology Group. <i>Blood</i> , 2011, 118, 2617-2617.	0.6	0
97	TET2 Mutations Are Associated with Poor Outcome in Pediatric AML: A Report From the Children's Oncology Group. <i>Blood</i> , 2011, 118, 569-569.	0.6	0
98	The Prognostic Effect of High WT1 Gene Expression in Pediatric AML Depends on WT1 SNP rs16754 Status: A Report From the Children's Oncology Group (COG). <i>Blood</i> , 2011, 118, 1444-1444.	0.6	0
99	Severe Toxicities During Pediatric Acute Myeloid Leukemia Chemotherapy: A Report From the Children's Oncology Group. <i>Blood</i> , 2010, 116, 1071-1071.	0.6	4
100	Identification of Post-Induction Minimal Residual Disease by Multidimensional Flow Cytometry Identifies Patients with AML at High Risk of Relapse and Poor Outcome- a Report From the Children's Oncology Group. <i>Blood</i> , 2010, 116, 1702-1702.	0.6	1
101	Conventional Cytogenetics, Molecular Profiling, and Flow Cytometric Response Data Allow the Creation of a Two-Tiered Risk-Group System for Risk-Based Therapy Allocation In Childhood AML- a Report From the Children's Oncology Group. <i>Blood</i> , 2010, 116, 761-761.	0.6	6
102	Flow Cytometric Assessment of Post Induction Response In Patients with Sub-Optimal Morphologic Response to Induction Chemotherapy- A Report From the Children's Oncology Group AML Protocol AAML0531. <i>Blood</i> , 2010, 116, 2740-2740.	0.6	0
103	The WT1 synonymous SNP rs16754 Is Associated with Higher mRNA Expression and Predicts Significantly Improved Outcome In Favorable-Risk Pediatric AML: a Report From the Children's Oncology Group. <i>Blood</i> , 2010, 116, 950-950.	0.6	0
104	Association of CD33 Expression Level with Disease Risk-Group Classification and Induction Response In Pediatric AML: A Report From the Children's Oncology Group. <i>Blood</i> , 2010, 116, 2732-2732.	0.6	6
105	Prognostic Implications of the IDH1 synonymous SNP rs11554137 In Pediatric and Adult AML: a Children's Oncology Group and Southwest Oncology Group Study. <i>Blood</i> , 2010, 116, 2737-2737.	0.6	1
106	High Mortality In Extreme Hyperleukocytosis In Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group. <i>Blood</i> , 2010, 116, 1072-1072.	0.6	0
107	High Expression of Neutrophil Elastase Predicts Improved Survival In Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group. <i>Blood</i> , 2010, 116, 2762-2762.	0.6	0
108	Oxidant Pathway Functional Polymorphisms Influence the Risk of Myeloid Leukemia/Transient Myeloproliferative Disorder In Children with Down Syndrome. <i>Blood</i> , 2010, 116, 1680-1680.	0.6	0

#	ARTICLE	IF	CITATIONS
109	CBL Mutations In Pediatric Acute Myelogenous Leukemia Are a Rare Event, a Report From the Children's Oncology Group.. Blood, 2010, 116, 1659-1659.	0.6	0
110	RUNX1 Mutations in Pediatric AML: A Report From the Children's Oncology Group.. Blood, 2009, 114, 2614-2614.	0.6	2
111	AAML0523: A Report From the Children's Oncology Group On the Safety of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Leukemia.. Blood, 2009, 114, 3076-3076.	0.6	4
112	Pathway Based Evaluation of Cytarabine Pharmacogenetics in Children with Acute Myeloid Leukemia.. Blood, 2009, 114, 2610-2610.	0.6	0
113	Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML – A Report From the Children's Oncology Group.. Blood, 2009, 114, 3115-3115.	0.6	0
114	High Expression of the Very Late Antigen (VLA)-4 (CD49d) Integrin Predicts for Reduced Risk of Relapse and Better Outcome in Pediatric Acute Myeloid Leukemia (AML): A Report From the Children's Oncology Group.. Blood, 2009, 114, 1592-1592.	0.6	0
115	Minimal Residual Disease Detection by Four-Color Multidimensional Flow Cytometry Identifies Pediatric AML Patients at High Risk of Relapse.. Blood, 2007, 110, 1429-1429.	0.6	9
116	Acute myeloid leukemia and Down Syndrome evolution of modern therapy?state of the art review. Pediatric Blood and Cancer, 2005, 44, 13-20.	0.8	79
117	Surveys: A tool to provoke thought and identify areas of need. Pediatric Blood and Cancer, 2005, 44, 205-206.	0.8	1
118	Increased Age at Diagnosis Has a Significantly Negative Effect on Outcome in Children With Down Syndrome and Acute Myeloid Leukemia: A Report From the Children's Cancer Group Study 2891. Journal of Clinical Oncology, 2003, 21, 3415-3422.	0.8	158
119	Transient Myeloproliferative Disorder, a Disorder With Too Few Data and Many Unanswered Questions: Does It Contain an Important Piece of the Puzzle to Understanding Hematopoiesis and Acute Myelogenous Leukemia?. Journal of Pediatric Hematology/Oncology, 2002, 24, 2-5.	0.3	44
120	Adenocarcinoma of Minor Salivary Gland Origin with Skeletal Metastasis in a Child. Pediatric Pathology & Laboratory Medicine: Journal of the Society for Pediatric Pathology, Affiliated With the International Paediatric Pathology Association, 1996, 16, 89-98.	0.3	1
121	ADENOCARCINOMA OF MINOR SALIVARY GLAND ORIGIN WITH SKELETAL METASTASIS IN A CHILD. Pediatric Pathology & Laboratory Medicine: Journal of the Society for Pediatric Pathology, Affiliated With the International Paediatric Pathology Association, 1996, 16, 89-98.	0.3	2
122	Diffuse bony metastases at presentation in a child with glioblastoma multiforme: A case report. Cancer, 1990, 66, 180-184.	2.0	51